Neoadjuvant Therapy for Non-small Cell Lung Cancer and Esophageal Cancer

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Apr 9

PMID 38590425

Authors

Yunlong He

Yaqi Zhao

Muhammad Luqman Akhtar

Yu Li

Mingyan E

Huan Nie

Affiliations

Soon will be listed here.

Abstract

As the major malignant tumors in the chest, non-small cell lung cancer (NSCLC) and esophageal cancer (EC) bring huge health burden to human beings worldwide. Currently, surgery is still the mainstay for comprehensive treatment for NSCLC and EC, but the prognosis is still poor as the results of cancer recurrence and distant metastasis. Neoadjuvant therapy refers to a single or combined treatment before surgery, aiming to improve the therapeutic effects of the traditional therapies. Unfortunately, the clinical outcomes and effects of neoadjuvant therapy are still controversial due to its apparent advantages and disadvantages, and different patients may respond differentially to the same scheme of neoadjuvant therapy, which makes it urgent and necessary to develop personalized scheme of neoadjuvant therapy for different individuals. Therefore, this review summarizes the novel schemes and strategies of neoadjuvant therapy, which may help to significantly improve of life quality of patients suffering from chest-related malignancies.

Citing Articles

Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression.

Mitrakas A, Kakouratos C, Lamprou I, Xanthopoulou E, Koukourakis M Cancers (Basel). 2025; 17(5).

PMID: 40075700 PMC: 11899603. DOI: 10.3390/cancers17050853.

Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies.

Chen Y, Qi F, Sun C, Jiang P, Xue X, Yang X Ther Adv Med Oncol. 2025; 17():17588359241312501.

PMID: 39781239 PMC: 11707791. DOI: 10.1177/17588359241312501.

Exploring the mechanism of 6-Methoxydihydrosanguinarine in the treatment of lung adenocarcinoma based on network pharmacology, molecular docking and experimental investigation.

Liu X, Ren Y, Qin S, Yang Z BMC Complement Med Ther. 2024; 24(1):202.

PMID: 38783288 PMC: 11119275. DOI: 10.1186/s12906-024-04497-z.

References

Roviello G, Iannone L, Bersanelli M, Mini E, Catalano M . The gut microbiome and efficacy of cancer immunotherapy. Pharmacol Ther. 2021; 231:107973. DOI: 10.1016/j.pharmthera.2021.107973. View

Rothschild S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A . SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol. 2021; 39(26):2872-2880. DOI: 10.1200/JCO.21.00276. View

Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer G, Fietkau R . Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2021; 8(1):e215445. PMC: 8603234. DOI: 10.1001/jamaoncol.2021.5445. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y . Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Surg. 2021; 156(5):444-451. PMC: 7970392. DOI: 10.1001/jamasurg.2021.0133. View

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

Hu J, Zhang L, Xia H, Yan Y, Zhu X, Sun F . Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 2023; 15(1):14. PMC: 9985263. DOI: 10.1186/s13073-023-01164-9. View

Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J . Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10):1830-1840. PMC: 10082285. DOI: 10.1200/JCO.22.02186. View

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

10.

Lim J, Yeo C . Update on adjuvant therapy in completely resected NSCLC patients. Thorac Cancer. 2021; 13(3):277-283. PMC: 8807337. DOI: 10.1111/1759-7714.14277. View

11.

Sawlani V, Taylor R, Rowley K, Redfern R, Martin J, Poptani H . Magnetic Resonance Spectroscopy for Differentiating Pseudo-Progression from True Progression in GBM on Concurrent Chemoradiotherapy. Neuroradiol J. 2013; 25(5):575-86. DOI: 10.1177/197140091202500511. View

12.

Wang W, Wang J, Liu S, Ren Y, Wang J, Liu S . An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer. Mol Cancer. 2022; 21(1):106. PMC: 9044593. DOI: 10.1186/s12943-022-01579-9. View

13.

Lee M, Mamon H, Hong T, Choi N, Fidias P, Kwak E . Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013; 18(3):281-7. PMC: 3607524. DOI: 10.1634/theoncologist.2012-0208. View

14.

Li C, Zhao S, Zheng Y, Han Y, Chen X, Cheng Z . Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2020; 144:232-241. DOI: 10.1016/j.ejca.2020.11.039. View

15.

Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y . Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. J Thorac Oncol. 2022; 18(1):93-105. DOI: 10.1016/j.jtho.2022.09.217. View

16.

Lordick F, Ott K, Krause B, Weber W, Becker K, Stein H . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8(9):797-805. DOI: 10.1016/S1470-2045(07)70244-9. View

17.

Li R, Morris S . Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev. 2007; 28(3):372-412. DOI: 10.1002/med.20109. View

18.

Lahiri A, Maji A, Potdar P, Singh N, Parikh P, Bisht B . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023; 22(1):40. PMC: 9942077. DOI: 10.1186/s12943-023-01740-y. View

19.

Song J, Shi W, Zhang Y, Sun M, Liang X, Zheng S . Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis. Onco Targets Ther. 2016; 9:6257-6263. PMC: 5066991. DOI: 10.2147/OTT.S111691. View

20.

Pless M, Stupp R, Ris H, Stahel R, Weder W, Thierstein S . Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015; 386(9998):1049-56. DOI: 10.1016/S0140-6736(15)60294-X. View